CD80-IgG1 Fc融合蛋白修饰的HepG2细胞对淋巴细胞抗肿瘤免疫的影响

目的：探讨CD80-IgG1 Fc段融合蛋白修饰的HepG2细胞对淋巴细胞抗肿瘤免疫的影响。方法：应用福建省临床免疫研究所构建的CD80-IgG1 Fc段融合蛋白，修饰肝癌细胞株HepG2细胞，用流式细胞术检测修饰的HepG2细胞上CD80的表达。将修饰的HepG2细胞与健康人外周血淋巴细胞混合后进行培养，分别应用MTT比色法、乳酸脱氢酶释放试验；检测经CD80-IgG1 Fc段融合蛋白修饰的HepG2细胞对外周血淋巴细胞增殖及其细胞毒性的影响。结果：CD80-IgG1Fc段融合蛋白可有效地结合于HepG2细胞膜上，结合的量在一定范围内与融合蛋白的浓度呈正相关（P＜0．05）。融合蛋白修饰的HepG2细胞可明显刺激外周血淋巴细胞活化增殖并增强CTL的细胞毒活性（P＜0．05）。结论：CD80在抗肿瘤免疫中起着重要作用，用CD80-IgG1Fc段融合蛋白修饰的HepG2肿瘤细胞能明显增强淋巴细胞的特异性抗肿瘤免疫，为CD80用于肿瘤免疫治疗的研究提供了实验依据.

Effect of HepG2 cells modified with CD80-IgG1 Fc fusion protein on anti-tumor immune response by lymphocytes

AIM: To investigate the anti-tumor immune response of lymphocytes elicited by HepG2 cells modified with CD80-IgG1 Fc fragment fusion protein(CD80-Fc). METHODS: HepG2 cells were modified with CD80-Fc, then the expression of CD80 on the cell surface was analyzed by flow cytometry(FCM). After mixed lymphocyte-tumour cell reaction(MLTR) of the modified HepG2 cells and peripheral lymphocytes of healthy volunteers, the proliferation and cytotoxicity of the lymphocytes were tested by MTT colorimetry and LDH release assay,respectively. RESULTS: CD80-Fc could be efficiently bound on HepG2 cells. HepG2 cells modified with CD80-Fc fusion protein dramatically elicited proliferation and cytotoxicity of normal lymphocytes. CONCLUSION: CD80 may play an important role in anti-tumour immune response. HepG2 cells modified with CD80-Fc fusion protein can elicited potent anti-tumor immune response. This fusion protein provides a convenient means for further potential use in immunotherapy of tumor.